Silence Therapeutics (NASDAQ:SLN – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They currently have a $55.00 target price on the stock. Chardan Capital’s target price suggests a potential upside of 333.07% from the company’s previous close.
A number of other brokerages have also recently issued reports on SLN. Jefferies Financial Group began coverage on Silence Therapeutics in a research note on Tuesday, September 3rd. They set a “buy” rating and a $40.00 price objective on the stock. Morgan Stanley reissued an “overweight” rating and issued a $49.00 target price on shares of Silence Therapeutics in a report on Tuesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, August 30th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $57.20.
Silence Therapeutics Trading Down 9.2 %
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $11.28 million. Silence Therapeutics had a negative return on equity of 58.28% and a negative net margin of 222.44%. On average, equities analysts predict that Silence Therapeutics will post -1.55 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC grew its holdings in Silence Therapeutics by 10.5% during the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock valued at $151,000 after buying an additional 667 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Silence Therapeutics during the 3rd quarter worth $56,000. Y Intercept Hong Kong Ltd lifted its position in shares of Silence Therapeutics by 22.9% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock worth $383,000 after purchasing an additional 3,923 shares during the period. Quarry LP purchased a new position in Silence Therapeutics in the second quarter valued at about $114,000. Finally, Marshall Wace LLP boosted its stake in Silence Therapeutics by 7.3% in the second quarter. Marshall Wace LLP now owns 149,397 shares of the company’s stock valued at $2,839,000 after acquiring an additional 10,206 shares in the last quarter. Institutional investors own 98.73% of the company’s stock.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Featured Stories
- Five stocks we like better than Silence Therapeutics
- Consumer Staples Stocks, Explained
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Earnings Per Share Calculator: How to Calculate EPS
- Top-Performing Non-Leveraged ETFs This Year
- Ride Out The Recession With These Dividend Kings
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.